Update shared on15 Jul 2025
Fair value Decreased 17%The significant downward revision in Cohance Lifesciences’ price target reflects lowered revenue growth forecasts and a sharply higher future P/E, resulting in a new consensus fair value of ₹1313.
WHAT'S IN THE NEWS
- Suven Pharmaceuticals Limited changed its name to Cohance Lifesciences Limited, with all company documents updated to reflect the new name.
- The board convened to discuss the effective date of an Amalgamation Scheme, the record date for share allotment under the scheme, and other related matters.
VALUATION CHANGES
Summary of Valuation Changes for Cohance Lifesciences
- The Consensus Analyst Price Target has significantly fallen from ₹1591 to ₹1313.
- The Future P/E for Cohance Lifesciences has significantly risen from 35.29x to 52.95x.
- The Consensus Revenue Growth forecasts for Cohance Lifesciences has significantly fallen from 65.5% per annum to 56.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.